Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-9340613-B2

Patent

Publication Date

2016-05-17

Expiration Date


Abstract

An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.

Core Innovation

The invention relates to anti-IL-6 antibodies and their fragments and variants, including human engineered antibodies, and isolated antibodies comprising a light chain variable region and a heavy chain variable region. The antibody binding site is defined by complementarity determining region sequences, including CDRL1, CDRL2, CDRL3, CDRH1, CDRH2, and CDRH3, with specific amino acid sequence patterns and SEQ ID NO references. The invention includes lyophilized pharmaceutical formulations of an isolated IL-6 antibody, where the light and heavy chain variable regions are characterized by the stated CDR sequences.

The document describes engineered antibodies with reduced immunogenicity, fully human frameworks, low immunogenicity, and neutralizing activity against IL-6, optionally with Fc engineering and effector function as described in the document. The invention further includes encoding nucleic acids, vectors, and host cells for expressing the specified anti-IL-6 antibodies, including transgenic animals and transgenic plants.

The invention also addresses pharmaceutical presentation and delivery concepts for anti-IL-6 antibodies, including stable or preserved solutions and lyophilized products. The lyophilized formulations are described with pharmaceutical carriers or diluents and excipients such as histidine buffer, sucrose, and polysorbate 80, and include packaging and labeling concepts for extended hold or use times. Multiple administration routes and delivery device types are described in the document, including pulmonary delivery systems such as nebulizers, inhalers, and metered dose inhalers.

Claims Coverage

The provided claim set includes one independent claim that defines a lyophilized pharmaceutical formulation, with inventive features centered on specific CDR sequence constraints for the light chain variable region and heavy chain variable region, as well as formulation presentation as lyophilized.

Lyophilized anti-IL-6 antibody formulation defined by CDR sequence patterns and SEQ ID NOs

A lyophilized pharmaceutical formulation of an isolated IL-6 antibody comprising at least one light chain variable region and one heavy chain variable region, where the light chain variable region includes CDRL1, CDRL2, and CDRL3 amino acid sequences defined by SEQ ID NOs and pattern constraints, and where the heavy chain variable region includes CDRH1, CDRH2, and CDRH3 amino acid sequences defined by SEQ ID NOs and pattern constraints.

Across the provided material, the claim coverage is directed to lyophilized formulations in which the isolated IL-6 antibody’s variable regions are constrained by specific CDR sequence patterns and SEQ ID NO-defined CDR amino acid sequences.

Stated Advantages

Therapeutic advantages of IL-6 inhibition are claimed for IL-6-mediated disorders.

Documented Applications

Therapeutic methods are described for osteoarthritis, systemic lupus erythematosus (SLE) and related manifestations including lupus nephritis and cutaneous lupus erythematosus, type II diabetes mellitus (T2DM), and chronic obstructive pulmonary disease (COPD).

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.